Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy

NCT ID: NCT01295619

Last Updated: 2016-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective study to evaluate the performance and safety of a new medical device used in case of cerebrospinal fluid (CSF) leakage after an elective cranial surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who consented to participate in the trial and fulfilled the preoperative inclusion and exclusion criteria underwent screening prior to surgical treatment. After dural suturing, if patients met the intra operative inclusion and exclusion criteria, they received I-020805. If necessary, autologous grafts were to be used to augment dural closure.

I-020805 was delivered from a double syringe applicator that creates a fine layer over the dura. This layer quickly sets within seconds to form a watertight seal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrospinal Fluid Leakage

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dura Sealant Cranial Craniotomy CSF leakage CSF leakage following cranial surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I-020805

This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.

Group Type EXPERIMENTAL

I-020805

Intervention Type DEVICE

A thin layer of I-020805 applied up to two times on the sutured dura mater

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

I-020805

A thin layer of I-020805 applied up to two times on the sutured dura mater

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Pre-operative

* Male or female of 18 years old or over
* Elective cranial procedure entailing a dural incision of at least 2 cm in length
* Requires a procedure involving surgical wound classification Class I/Clean
* Signed informed consent form
* Negative pregnancy test at screening for women of childbearing potential and agreeing to use an acceptable birth control method or abstinence until 90 days post-surgery

Intra-operative

* Surgical wound classification Class I/Clean
* Dural margin from bony edges of at least 3 mm throughout
* Spontaneous expression of CSF assessed visually or a CSF leakage upon Valsalva maneuver

Exclusion Criteria

Pre-operative

* Cranial procedure requiring translabyrinthine, transoral and/or any procedure penetrating the air sinus or mastoid air cells
* Presence of symptomatic hydrocephalus
* Pre-existing external ventricular drainage or lumbar CSF drain
* Radiotherapy in the planned surgical region which ended within 3 months prior to planned surgery
* Presence of systemic infection
* Known history of hemophilia or other clinically significant coagulopathy
* Known oral anticoagulant use
* Pregnancy or breast feeding
* Known allergy to any components of I-020805
* Previous participation in this trial or any investigational drug or device study within 30 day of screening
* Known clinically significant organ or systemic diseases
* Known or suspected non-compliance with trial procedures

Intra-operative

* Patient not meeting the pre-operative eligibility criteria
* Not able to tolerate a Valsalva maneuver
* Gap of more than 2 mm remaining after primary closure of dura
* Use of synthetic or non-autologous duraplasty material
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kuros Biosurgery AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Virginia Jamieson, MD

Role: STUDY_DIRECTOR

Kuros Biosurgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charite Universitätsmedizin (01)

Berlin, , Germany

Site Status

Orszagos Idegtudomanyi Intezet (11)

Budapest, , Hungary

Site Status

Debreceni Tudomanyegyetem (12)

Debrecen, , Hungary

Site Status

Szegedi Tudomanyegyetem (10)

Szeged, , Hungary

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Hungary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS I-020805/01

Identifier Type: -

Identifier Source: org_study_id